Cargando…
The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes
BACKGROUND: Connective tissue growth factor (CTGF) has been implicated in the cardiac and kidney complications of type 2 diabetes, and the CTGF −945 G/C polymorphism is associated with susceptibility to systemic sclerosis, a disease characterised by tissue fibrosis. This study investigated the assoc...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439260/ https://www.ncbi.nlm.nih.gov/pubmed/22533709 http://dx.doi.org/10.1186/1475-2840-11-42 |
_version_ | 1782242965950824448 |
---|---|
author | Patel, Sheila K Wai, Bryan MacIsaac, Richard J Grant, Sharon Velkoska, Elena Ord, Michelle Panagiotopoulos, Sianna Jerums, George Srivastava, Piyush M Burrell, Louise M |
author_facet | Patel, Sheila K Wai, Bryan MacIsaac, Richard J Grant, Sharon Velkoska, Elena Ord, Michelle Panagiotopoulos, Sianna Jerums, George Srivastava, Piyush M Burrell, Louise M |
author_sort | Patel, Sheila K |
collection | PubMed |
description | BACKGROUND: Connective tissue growth factor (CTGF) has been implicated in the cardiac and kidney complications of type 2 diabetes, and the CTGF −945 G/C polymorphism is associated with susceptibility to systemic sclerosis, a disease characterised by tissue fibrosis. This study investigated the association of the CTGF −945 G/C promoter variant with cardiac complications (left ventricular (LV) hypertrophy (LVH), diastolic and systolic dysfunction) and chronic kidney disease (CKD) in type 2 diabetes. METHODS: The CTGF −945 G/C polymorphism (rs6918698) was examined in 495 Caucasian subjects with type 2 diabetes. Cardiac structure and function were assessed by transthoracic echocardiography. Kidney function was assessed using estimated glomerular filtration rate (eGFR) and albuminuria, and CKD defined as the presence of kidney damage (decreased kidney function (eGFR <60 ml/min/1.73 m(2)) or albuminuria). RESULTS: The mean age ± SD of the cohort was 62 ± 14 years, with a body mass index (BMI) of 31 ± 6 kg/m(2) and median diabetes duration of 11 years [25(th), 75(th) interquartile range; 5, 18]. An abnormal echocardiogram was present in 73% of subjects; of these, 8% had LVH alone, 74% had diastolic dysfunction and 18% had systolic ± diastolic dysfunction. CKD was present in 42% of subjects. There were no significant associations between the CTGF −945 G/C polymorphism and echocardiographic parameters of LV mass or cardiac function, or kidney function both before and after adjustment for covariates of age, gender, BMI, blood pressure and hypertension. CTGF −945 genotypes were not associated with the cardiac complications of LVH, diastolic or systolic dysfunction, nor with CKD. CONCLUSIONS: In Caucasians with type 2 diabetes, genetic variation in the CTGF −945 G/C polymorphism is not associated with cardiac or kidney complications. |
format | Online Article Text |
id | pubmed-3439260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34392602012-09-12 The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes Patel, Sheila K Wai, Bryan MacIsaac, Richard J Grant, Sharon Velkoska, Elena Ord, Michelle Panagiotopoulos, Sianna Jerums, George Srivastava, Piyush M Burrell, Louise M Cardiovasc Diabetol Original Investigation BACKGROUND: Connective tissue growth factor (CTGF) has been implicated in the cardiac and kidney complications of type 2 diabetes, and the CTGF −945 G/C polymorphism is associated with susceptibility to systemic sclerosis, a disease characterised by tissue fibrosis. This study investigated the association of the CTGF −945 G/C promoter variant with cardiac complications (left ventricular (LV) hypertrophy (LVH), diastolic and systolic dysfunction) and chronic kidney disease (CKD) in type 2 diabetes. METHODS: The CTGF −945 G/C polymorphism (rs6918698) was examined in 495 Caucasian subjects with type 2 diabetes. Cardiac structure and function were assessed by transthoracic echocardiography. Kidney function was assessed using estimated glomerular filtration rate (eGFR) and albuminuria, and CKD defined as the presence of kidney damage (decreased kidney function (eGFR <60 ml/min/1.73 m(2)) or albuminuria). RESULTS: The mean age ± SD of the cohort was 62 ± 14 years, with a body mass index (BMI) of 31 ± 6 kg/m(2) and median diabetes duration of 11 years [25(th), 75(th) interquartile range; 5, 18]. An abnormal echocardiogram was present in 73% of subjects; of these, 8% had LVH alone, 74% had diastolic dysfunction and 18% had systolic ± diastolic dysfunction. CKD was present in 42% of subjects. There were no significant associations between the CTGF −945 G/C polymorphism and echocardiographic parameters of LV mass or cardiac function, or kidney function both before and after adjustment for covariates of age, gender, BMI, blood pressure and hypertension. CTGF −945 genotypes were not associated with the cardiac complications of LVH, diastolic or systolic dysfunction, nor with CKD. CONCLUSIONS: In Caucasians with type 2 diabetes, genetic variation in the CTGF −945 G/C polymorphism is not associated with cardiac or kidney complications. BioMed Central 2012-04-26 /pmc/articles/PMC3439260/ /pubmed/22533709 http://dx.doi.org/10.1186/1475-2840-11-42 Text en Copyright ©2012 Patel et al.; licensee BioMed Central Ltd; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Investigation Patel, Sheila K Wai, Bryan MacIsaac, Richard J Grant, Sharon Velkoska, Elena Ord, Michelle Panagiotopoulos, Sianna Jerums, George Srivastava, Piyush M Burrell, Louise M The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes |
title | The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes |
title_full | The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes |
title_fullStr | The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes |
title_full_unstemmed | The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes |
title_short | The CTGF gene −945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes |
title_sort | ctgf gene −945 g/c polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439260/ https://www.ncbi.nlm.nih.gov/pubmed/22533709 http://dx.doi.org/10.1186/1475-2840-11-42 |
work_keys_str_mv | AT patelsheilak thectgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT waibryan thectgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT macisaacrichardj thectgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT grantsharon thectgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT velkoskaelena thectgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT ordmichelle thectgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT panagiotopoulossianna thectgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT jerumsgeorge thectgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT srivastavapiyushm thectgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT burrelllouisem thectgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT patelsheilak ctgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT waibryan ctgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT macisaacrichardj ctgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT grantsharon ctgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT velkoskaelena ctgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT ordmichelle ctgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT panagiotopoulossianna ctgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT jerumsgeorge ctgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT srivastavapiyushm ctgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes AT burrelllouisem ctgfgene945gcpolymorphismisnotassociatedwithcardiacorkidneycomplicationsinsubjectswithtype2diabetes |